Sanofi asthma drug seen as potential game changer

A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage trial, making it a potential game changer for patients with moderate to severe disease,Locate different kitchen cabinet refacing companies Used construction machinerycabinet makers in your area and get them to come and check out your kitchen. researchers said on Tuesday."Overall, these are the most exciting data we've seen in asthma in 20 years," said Dr. Sally Wenzel, lead investigator for the 104-patient study of dupilumab, an injectable treatment being developed by Regeneron Pharmaceuticals Inc and French drugmaker Sanofi.This is why there is need for a comprehensive marketing platform Spring cone crusherthere is also a need for a high quality training program to enable marketers become familiar with the most up to date learning processes.The drug also met all its secondary goals, such as improving symptoms and lung function and reducing the need for standard drugs called beta agonists.Although far larger trials will be needed to confirm findings from the "proof of concept" study, researchers expressed optimism. They noted that dupilumab has also shown the ability to tame atopic dermatitis, or severe eczema, an allergic condition that is not well controlled by current treatments.
Results of the 12-week asthma study are being presented on Tuesday at the annual scientific meeting of the American Thoracic Society in Philadelphia.The medicine, if approved, could hold promise for patients with moderate to severe persistent asthma that is not well controlled by standard drugs."We have been treating asthma with sort of Band-Aid therapies that didn't get at the underlying causes," Wenzel said in an interview, adding that dupilumab could be an important step in going to the root of the problem.Wenzel, director of the Asthma Institute at the University of Pittsburgh, said other drugmakers have tested medicines that block one or both of the proteins, but without success.The trial recruited patients with high levels of eosinophils, a biomarker that shows immune system cells called type 2 helper T cells (Th2 cells) associated with allergy and asthma have been activated.Such patients were deemed likely to benefit from treatment.All patients initially stayed on their standard asthma treatments, meaning medium-to-high doses of inhaled glucocorticoids,It also has simple structure big production capacity professional Cleaning brush wholesalers from China low manufacturing cost so that it is used by priority at suitable situation.When buying a knife it is also a good idea to invest in a sharpening tool such as a sharpening steeltyres and wheels service & repair equipment a whetstone Regular sharpening will ensure your blades stay keen. as well as long-acting beta agonists.They are expensive as they present the purchaser with their priceless beauty Curshermesmerizing elegance that will not only add to the glamorous sense in performance but is also a symbol of luxury. But patients gradually tapered off on those drugs and were no longer taking either of them after 9 weeks.